Reviews: Aspirin resistance: Biological and clinical implications

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 1, 2008, Pages 5-12

  Tseeng, Stephanie ^a   Arora, Rohit ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acetylsalicylic acid resistance; Aggregation; Aspirin resistance; Cyclooxygenase 1; Platelet inhibitor; Thromboxane A2; Thromboxane inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CATECHOLAMINE; ISOPROSTANE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT;

DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; PATHOPHYSIOLOGY; THROMBOCYTE; THROMBOSIS;

ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 39049115011     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407310869     Document Type: Review

References (49)

1. Rosamond W., Flegal K., Friday G.,, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007 ; 115: e69 - e171.
2. Hankey GJ, Eikelboom JW Aspirin resistance. Lancet. 2006 ; 367: 606-617.
3. McAdam BF, Catella-Lawson F., Mardini IA, Kapoor S., Lawson JA, FitzGerald GA Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999 ; 96: 272-277.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994 ; 308: 81-106.
5. Smith WL, Garavito RM, DeWitt DL Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J Biol Chem. 1996 ; 271: 33157-33160.
6. Cambria-Kiely JA, Gandhi PJ Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis. 2002 ; 14: 51-58.
7. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 ; 69: 1366-1372.
8. Weksler BB, Pett SB, Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983 ; 308: 800-805.
9. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000 ; 101: 1206-1218.
10. Sanderson S., Emery J., Baglin T., Kinmonth AL Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005 ; 142: 370-380.
11. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH The effect of chronic platelet inhibition with low dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from Physicians Health Study. Am Heart J. 1991 ; 122: 1588-1592.
12. Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86.
13. Tantry US, Bliden KP, Gurbel PA Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005 ; 46: 1705-1709.
14. Mueller MR, Salat A., Stangl P., et al. Variable platelet response to low dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997 ; 78: 1003-1007.
15. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007 ; 153: 175-181.
16. Gum PA, Kottke-Marchant K., Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001 ; 88: 230-235.
17. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006 ; 47: 27-33.
18. Chen WH, Lee PY, Ng W., Tse HF, Lau CP Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004 ; 43: 1122-1126.
19. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin ? Am Heart J. 2004 ; 147: 293-300.
20. Pamukcu B., Oflaz H., Oncul A., et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis. 2006 ; 22: 103-110.
21. Hobikoglu GF, Norgaz T., Aksu H., et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med. 2005 ; 207: 59-64.
22. Pamukcu B., Oflaz H., Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J. 2005 ; 149: 675-680.
23. Alberts MJ, Bergman DL, Molner E., Jovanovic BD, Ushiwata I., Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004 ; 35: 175-178.
24. Macchi L., Christiaens L., Brabant S., et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003 ; 42: 1115-1119.
25. Andersen K., Hurlen M., Arnesen H., Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002 ; 108: 37-42.
26. Roller RE, Dorr A., Ulrich S., Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis. 2002 ; 13: 277-281.
27. Cattaneo M. Laboratory detection of "aspirin resistance": what test should we use (if any) ? Eur Heart J. 2007 ; 28: 1673-1675.
28. Pamucku B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis. 2006 ; 23: 213-222.
29. Feuring M., Schultz A., Losel R., Wehling M. Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin Thromb Hemost. 2005 ; 31: 411-415.
30. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J. 1998 ; 135: S170 - S178.
31. Gonzalez-Conejero R., Rivera J., Corral J., Acuna C., Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure ? Stroke. 2005 ; 36: 276-280.
32. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis DA, Diodati JG A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007 ; 28: 1702-1708.
33. Cardinal DC, Flower RJ The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods. 1980 ; 3: 1350-1358.
34. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003 ; 1: 1710-1713.
35. Ohmori T., Yatomi Y., Nonaka T., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006 ; 4: 1271-1278.
36. Catella F., Fitzgerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res. 1987 ; 47: 647-656.
37. Roller RE, Dorr A., Ulrich S., Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis. 2002 ; 13: 277-281.
38. Patrono C., Coller B., Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness and side effects. Chest. 2001 ; 119: 39S - 63S.
39. Cambria-Kiely JA, Gandhi PJ Possible mechanisms of aspirin resistance. J Thromb Thrombolysis. 2002 ; 13: 49-56.
40. Blache D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol. 1995 ; 268: H679 - H685.
41. Ichiki K., Ikeda H., Haramaki N., Ueno T., Imaizumi T. Long term smoking impairs platelet derived nitric oxide release. Circulation. 1996 ; 94: 3109-3114.
42. Wallen NH, Held C., Rehnqvist N., Hjemdahl P. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J. 1997 ; 18: 807-815.
43. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994 ; 89: 1951-1957.
44. Anfossi G., Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest. 1996 ; 26: 353-370.
45. Pamukcu B., Oflaz H., Acar RD, et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J Thromb Thrombolysis. 2005 ; 20: 17-22.
46. Christiaens L., Macchi L., Herpin D., et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 2003 ; 108: 115-119.
47. Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol. 2005 ; 95: 805-808.
48. Stepień E., Szułdrzyński K., Branicka A., et al. The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins. Pol Arch Med Wewn. 2007 ; 117: 33-40.
49. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007 ; 167: 1593-1599.